NASDAQ:APLMW Apollomics (APLMW) Stock Price, News & Analysis $0.01 +0.00 (+15.83%) As of 03:05 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsNews and TrendsSEC Filings About Apollomics Stock (NASDAQ:APLMW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Apollomics alerts:Sign Up Key Stats Today's Range$0.0115▼$0.013950-Day Range$0.0111▼$0.019952-Week Range$0.01▼$0.23Volume6,848 shsAverage Volume56,486 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Apollomics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and potential commercialization of novel oncology therapies. Since its founding, the company has concentrated on creating targeted and immuno-oncology candidates designed to address unmet needs in solid tumors. Apollomics maintains headquarters in the United States with key research operations in China, leveraging a dual-site strategy to accelerate global development timelines. The company’s pipeline encompasses a range of therapeutic modalities, including monoclonal antibodies, antibody-drug conjugates and bispecific constructs. Apollomics applies proprietary target-identification and antibody-engineering platforms to advance multiple programs from preclinical stages into Phase 1 and Phase 2 clinical trials. Its lead candidates are being evaluated in various solid tumor indications, with data readouts expected to inform next-stage development and potential registration strategies. With operations spanning both the U.S. and China, Apollomics is positioned to navigate regulatory pathways in major markets while leveraging cost-efficient R&D infrastructure. The company’s management team comprises experienced executives with backgrounds in oncology drug development, clinical operations and regulatory affairs. Apollomics continues to explore strategic collaborations to broaden its pipeline and maximize the clinical and commercial potential of its drug candidates.AI Generated. May Contain Errors. Read More Receive APLMW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Apollomics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APLMW Stock News HeadlinesApollomics Announces $10 Million Private Placement TransactionAugust 11, 2026 | globenewswire.comApollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in AsiaJune 24, 2026 | globenewswire.com“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI company holding 150 patents for technology that processes information up to 1,000 times faster than standard AI. Wall Street projects the company's sales to more than triple in the coming year, and Brown notes it's roughly the same size Nvidia was a decade ago, with a key catalyst set for November 11.September 16 at 1:00 AM | Brownstone Research (Ad)Apollomics Reports First Half 2025 Financial ResultsDecember 22, 2025 | globenewswire.comApollomics Announces Changes to its Board of Directors and Composition of CommitteesNovember 17, 2025 | globenewswire.comApollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing CancellationOctober 15, 2025 | globenewswire.comApollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing CancellationOctober 15, 2025 | globenewswire.comApollomics, Inc. Company Operational Continuity UpdateOctober 13, 2025 | globenewswire.comSee More Headlines APLMW Stock Analysis - Frequently Asked Questions How have APLMW shares performed this year? Apollomics' stock was trading at $0.0111 at the beginning of the year. Since then, APLMW stock has increased by 8.1% and is now trading at $0.0120. How do I buy shares of Apollomics? Shares of APLMW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/16/2026Next Earnings (Estimated)9/24/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 APLMW's financial health is in the Yellow zone, according to TradeSmith. APLMW has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:APLMW CIK1944885 Webwww.apollomicsinc.com Phone650-209-4055FaxN/AEmployees59Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$8.50 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:APLMW) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredGold majors have a big problemNewmont spent 15 billion dollars acquiring Newcrest in 2023, the largest deal in gold mining history. Yet prod...Golden Portfolio | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredThe national debt just passed $39 trillionThe U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40...US Gold Bureau | Sponsored“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...Brownstone Research | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
